Proposal for an innovating business model for supporting biotechnology companies, ecosystem and their founders
Requires Subscription or Fee PDF

Keywords

biotechnology
business model
paradigm
collaboration
resource allocation

Abstract

The pharmaceutical industry has been revolutionized by the new biotechnology companies during the last years. Facing patent expirations, lack of innovation and depleting product pipelines, the important structures turned to the funding of small biotechnology companies aimed at research and intellectual property securization. Alliances are primordial in the current economic climate. The market growth was questioned for years, but biotechnology companies shifted to product-driven strategies and the market performance has been verified during the last decade. Researchers still face challenges in transforming their science into businesses. They need to be fully equipped, and accompanied towards the right objectives to ensure the sustainability of the market as a whole.
https://doi.org/10.5912/jcb820
Requires Subscription or Fee PDF

References

Pfeffer, J. and Salancik, G. (1978). The External Control of Organizations: A Resource Dependence Perspective. Administrative Science Quarterly, 23(2), p.358.

Wang, C. and Wu, L. (2012). Team member commitments and start-up competitiveness. Journal of Business Research, 65(5), pp.708-715.

Lee, C., Lee, K. and Pennings, J. (2001). Internal capabilities, external networks, and performance: a study on technology-based ventures. Strategic Management Journal, 22(6-7), pp.615-640.

Houghton, S., Smith, A. and Hood, J. (2009). The influence of social capital on strategic choice: An examination of the effects of external and internal network relationships on strategic complexity. Journal of Business Research, 62(12), pp.1255-1261.

Powell, W. (1990). Neither market nor hierarchy: network forms of organization. Research in Organizational Behaviour, 12, pp.295-336.

Powell, W. (1998). Learning from Collaboration: Knowledge and Networks in the Biotechnology and Pharmaceutical Industries. California Management Review, 40(3), pp.228-240.

Deeds, D.L., and Hill, C.W.L. (1996) Strategic alliances, complimentary assets and new product development: An empirical study of entrepreneurial biotechnology firms. Journal of Business Venturing 11(1):41–55.

Shan, W., Walker, G., and Kogut, B. (1994) Interfirm cooperation and start-up innovation in the biotechnology industry. Strategic Management Journal 15: 387–394.

Gulati, R. (1999). Network location and learning: the influence of network resources and firm capabilities on alliance formation. Strat. Mgmt. J., 20: 397–420

Shimasaki, C. (2013). Biotechnology Entrepreneurship: Starting, Managing, and Leading Biotech Companies. Academic Press.

Pisano, G. (1991). The governance of innovation: Vertical integration and collaborative arrangements in the biotechnology industry. Research Policy, 20(3), pp.237-249.

Gurdon, M. and Samsom, K. (2010). A longitudinal study of success and failure among scientist-started ventures. Technovation, 30(3), pp.207-214.

Association of University Technology Managers (AUTM) (2016). AUTM - About Technology Transfer. [online] Available at: http://www.autm.net/autm-info/about-tech-transfer/about-technology-transfer/

Klein, P. G. (2008). Opportunity discovery, entrepreneurial action, and economic organization. Strategic Entrepreneurship Journal, 4, 175–90.

McMullen, J. S. and Shepherd, D. A. (2006). Entrepreneurial action and the role of uncertainty in the theory of the entrepreneur. Academy of Management Review, 31, 132–52.

van Werven, R., Bouwmeester, O. and Cornelissen, J. (2015). The power of arguments: How entrepreneurs convince stakeholders of the legitimate distinctiveness of their ventures. Journal of Business Venturing, 30(4), pp.616-631.

Fallowfield, L., Jenkins, V., Farewell, V., Saul, J., Duffy, A. and Eves, R. (2002). Efficacy of a Cancer Research UK communication skills training model for oncologists: a randomised controlled trial. The Lancet, 359(9307), pp.650-656.

Thumm, N. (2001). Management of Intellectual Property Rights in European Biotechnology Firms. Technological Forecasting and Social Change, 67(2-3), pp.259-272.

Baker, A. (2003). Opinion piece: Biotechnology's growth–innovation paradox and the new model for success. Journal of Commercial Biotechnology, 9(4), pp.286-288.

Forbes, D., Borchert, P., Zellmer-Bruhn, M. and Sapienza, H. (2006). Entrepreneurial Team Formation: An Exploration of New Member Addition. Entrepreneurship Theory and Practice, 30(2), pp.225-248.

Unless specified by prior arrangement, the author agrees to the following terms and assurances:

  1. For myself and on behalf of the other authors listed on this work, I assign to thinkBiotech LLC the copyright* in the contribution for the full term throughout the world.
  2. I/we further give to the following assurances
    1. I am the sole author of the contribution, or, if not, I have the written authority of the other authors to transfer the copyright* to thinkBiotech LLC and give these warranties;
    2. I and (where appropriate) the other authors are entitled to transfer the copyright to thinkBiotech LLC and no one else would be entitled to prevent us from publishing the contribution;
    3. To the best of my/our knowledge, all the facts in the contribution are true and accurate;
    4. The content of the contribution is entirely original to me (and where appropriate to the other authors) or, if not, the written permission of the owner of the copyright in any material copied from elsewhere has been obtained for all media (all such permissions to be attached to the contribution as supplementary files);
    5. Nothing in the contribution is obscene or libellous;
    6. Nothing in the contribution infringes any duty of confidentiality which I/or the other authors may owe to anyone else.
    7. I and/or the other authors have obtained the appropriate clearances from my/our employer(s) or other concerned institution(s).
* Works by US government employees prepared as part of official duties are in the public domain and the authors are therefore exempt from copyright assignment.